Medtronic Infuse Bone Graft Articles

Minneapolis, MN: A federal lawsuit into the marketing of the Medtronic Infuse bone graft has reportedly ended with no charges being filed against Medtronic. The investigation looked into allegations that Medtronic illegally marketed its bone graft device. Meanwhile, another Medtronic lawsuit, alleging Medtronic Inc. downplayed the risks associated with the Infuse, has been filed.

New York, NY: A Medtronic lawsuit brought by disgruntled shareholders has been settled with the decision by the defendant to pay $85 million. The Associated Press reports the manufacturer of medical devices agreed to the settlement in an effort to put behind them allegations surrounding the Medtronic infuse bone graft and Infuse bone repair protein.

San Diego, CA: Steve had a Medtronic Infuse bone graft implanted two years ago. The first two bone grafts he had previously with human bone were successful, but the Medtronic bone graft has been a total failure. "If I have to go through another, riskier surgery, I'll be getting a lawyer," he says.

Minneapolis, MN: Although it is not illegal to use an off-label (not FDA approved) medical device in surgical procedures, it is illegal to promote off-label use, and that is why Medtronic, the manufacturer of the Medtronic Infuse Bone Graft is in trouble financially. About 85 percent of Infuse procedures were used off-label, allegedly attributable to Medtronic’s aggressive off-label promotional campaign.

Seattle, WA: When Eileen found out that her surgeon used a Medtronic Infuse Bone Graft off-label, she was angry, to say the least. "There was never a discussion that this medical device was even used off-label," she says. "I am now told there is nothing they can do for the pain and I should have a Spinal Cord Implant."

New York, NY: Defective medical device attorneys are filing lawsuits against Medtronic for marketing its InFuse Bone Graft off-label, particularly for neck surgery. A number of personal injury lawsuits and a wrongful death suit (a California woman died after neck surgery) have also been filed against Medtronic.

Washington, DC: According to media reports, doctors who were paid to study Medtronic's Amplify, which contains recombinant human bone morphogenetic protein-2, or rhBMP-2, failed to disclose a possible increased risk for cancer in patients who received the treatment on study.

New York, NY: Medtronic Inc, has been ordered to produce documents pertaining to the safety of its Medtronic Infuse Bone Graft protein compound by a federal judge hearing a securities lawsuit filed against the company.

New York, NY: A review article published on Tuesday in The Spine Journal is sounding the alarm over data on Medtronic’s Infuse Bone Graft. Co-authored by three US-based physicians, the article states that in 13 trials which included 780 patients, industry funded researchers failed to report a single adverse event involving Infuse.

Washington, DC: Further to concerns about financial conflict of interest stemming from reports of physicians with financial ties to the medical device company, Medtronic, a senate committee has been established to investigate whether or not those physicians were aware of the serious complications associated with Medtronic's spinal device, Medtronic Infuse, and if so, why they failed to disclose those adverse events in journal papers.